IN8bio, Inc. (INAB)
| Market Cap | 137.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 18.75M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,980 |
| Open | 7.40 |
| Previous Close | 7.00 |
| Day's Range | 7.30 - 7.75 |
| 52-Week Range | 6.10 - 10.32 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 15.50 (+112.0%) |
| Est. Earnings Date | Nov 5, 2021 |
About INAB
IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct...
Financial Performance
Financial StatementsNews
IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies u...
IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Confer...
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leuke...
The first cohort has completed dosing with IN8bio's donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) o...
IN8bio Announces Pricing of Initial Public Offering
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell ther...
IN8bio Launches Proposed Initial Public Offering
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8bio” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery...
IN8bio IPO Registration Document (S-1)
IN8bio, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).
After name change and dropped IPO, IN8bio tries again to boost its cancer pipeline
IN8bio has trod an unusual path to an IPO but now has revived its once-dropped attempt.